Vitae Pharmaceuticals — Corporate Update (March 2016)
21 slides from Vitae Pharmaceuticals's corporate update, Mar 16, 2016
Slide 1: Disclaimer Regarding Forward Looking Statements
Disclaimer Regarding Forward Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this pre
Slide 2: Agenda
Agenda Welcome and Introduction J. Hatfield In-Depth Description of Data PASI score efficacy Biomarker data Safety / tolerability J. Hatfield R. Gregg External Expert’s Assessment of Data J. Krueger Next Steps / Close J. Hatfield
Slide 3: VTP-43742 Ph 2a Proof-of-Concept Trial Endpoints and Goal
VTP-43742 Ph 2a Proof-of-Concept Trial Endpoints and Goal Endpoints: Clinical efficacy % change in PASI score from baseline Biomarker response Plasma cytokine level changes Gene expression changes of pro-inflammatory cytokines from skin biopsies Cell histology and immunohistochemistry changes from s
Slide 4: % Change in PASI Clinical Score Cohort 1 350mg
% Change in PASI Clinical Score Cohort 1 - 350 mg Dose Group Cohort 1 350mg VTP-43742 -23% Placebo +1% Net PASI % Change -24% Individual patient PASI score changes shown, with pooled placebo Cohort 1 change vs baseline significant at p = 0.015 Pooled Placebo -80 -60 -40 -20 0 20 40 % D PASI Day 28 V
Slide 5: % Change in PASI Clinical Score Cohort 2 700mg
% Change in PASI Clinical Score Cohort 2 - 700 mg Dose Group Cohort 2 700mg VTP-43742 -29% Placebo +1% Net PASI % Change -30% Individual patient PASI score changes shown, with pooled placebo Cohort 2 change vs baseline significant at p = 0.003 Pooled Placebo -80 -60 -40 -20 0 20 40 % D PASI Day 28 V
Slide 6: Historical Perspective of 4 versus 12 Week Efficacy
PASI at 12 weeks (Injectable Therapy) % Change in PASI Historical Perspective of 4 versus 12 Week Efficacy PASI at 4 weeks (Oral Therapy) Psoriasis therapies require 12+ weeks to achieve full efficacy In published psoriasis trials, 4 week efficacy ranges from approximately ¼ to ¾ of 12 week efficacy
Slide 7: VTP-43742 PK and PD
VTP-43742 PK and PD Drug Exposure and % PASI Change by Week Concentration ng/ml Days of Trial 0 7 14 21 28 Days of Trial % Change in PASI Net of Placebo Drug Exposure by Week % PASI Net of Placebo by Week IC90 (n = 24) (n = 24) -35 -30 -25 -20 -15 -10 -5 0 350mg 700mg
Slide 8: VTP-43742 % PASI at 4 Weeks with Historical 12 Week Data
VTP-43742 % PASI at 4 Weeks with Historical 4 and 12 Week Data * * * % improvement in PASI score PASI at 12 weeks (Injectable Therapy) PASI at 4 weeks (Oral Therapy) * typical placebo response used to determine net efficacy – 15% at 4w, 22% at 12w PASI at 12 weeks (Oral Therapy) PASI at 4 weeks (Inj
Slide 9: VTP-43742: Biomarker Analyses
VTP-43742: Biomarker Analyses Initial Analyses Focused on Pro-Inflammatory Cytokines Initial Biomarker Analyses Plasma Cytokines IL-17A IL-17F Skin Cytokines IL-17A IL-17F Biomarker Analyses Underway Full spectrum of transcriptional profiling, including IL-21, IL-22, GM-CSF, IL-23R Immunohistochemis
Slide 10: Biomarker Analyses: Plasma IL-17A
Biomarker Analyses: Plasma IL-17A % Change on Day 28 vs Baseline Pooled Placebo 700mg p < 0.0001 67 Pooled Placebo 350mg p = 0.016 -80 -60 -40 -20 0 20 -80 -60 -40 -20 0 20 % D Plasma Il - 17A Day 28
Slide 11: Biomarker Analyses: Plasma IL-17F
Biomarker Analyses: Plasma IL-17F % Change on Day 28 vs Baseline Pooled Placebo Pooled Placebo 350mg 700mg p < 0.0001 p < 0.0001 -100 -80 -60 -40 -20 0 20 40 60 % D Plasma IL - 17F at Day 28 -100 -80 -60 -40 -20 0 20 40 60
Slide 12: Biomarker Analyses: Skin IL-17A
Biomarker Analyses: Skin IL-17A % Change on Day 28 vs Baseline 302 Placebo 350mg 700mg Placebo Skin biopsies required an additional consent; fewer patients participated -100 -50 0 50 100 150 -100 -50 0 50 100 150 % D IL - 17A Day 28
Slide 13: Biomarker Analyses: Skin IL-17F
Biomarker Analyses: Skin IL-17F % Change on Day 28 vs Baseline Placebo 350mg 700mg Placebo p = 0.0003 p = 0.0015 -100 -50 0 50 100 -100 -50 0 50 100 % D IL - 17F Day 28
Slide 14: Safety / Tolerability
Safety / Tolerability VTP-43742 generally well-tolerated No SAEs Elevations in transaminases observed in four patients in 700mg cohort Did not meet any stopping rules of the trial None of the patients were discontinued; no action required No related elevation in bilirubin; no sign of liver damage Fu
Slide 15: VTP-43742 Trial Enrollment
VTP-43742 Trial Enrollment Concentration ng/ml Days of Trial Drug Exposure by Week IC90 1st cohort (350mg) demonstrated drug exposures clearly exceeding the estimated IC90; the 2nd cohort (700mg) exceeded estimated IC90 by ~5X The next planned dose cohort (1050mg) was not initiated due to transamina
Slide 16: Dr. Krueger Call-In Discussion
Dr. Krueger Call-In Discussion Leading Advisor to Industry for Psoriasis, TH17 Pathway What is your assessment of the results from this initial proof-of-concept trial with first-in-class RORt inhibitor VTP-43742? PASI % change efficacy Biomarker data Overall assessment Calling in: James G. Krueger,
Slide 17: Next Steps
Next Steps The Company believes these data validate RORt as a therapeutic target for autoimmune disorders Next Steps Initiate 16 week trial to assess full efficacy of first-in-class RORt inhibitor VTP-43742, planned by end of year 2016
Slide 18: Next Steps
Pharmaceuticals Next Steps Vi tae The Company believes these data validate ROR;t as a therapeutic target for autoimmune disorders Next Steps Initiate 16 week trial to assess full efficacy of first-in-class ROR;t inhibitor VTP-43742, planned by end of year 2016 Vitae Pharmaceuticals, Inc. March 2016
Slide 19: VTP-43742 POC Trial Summary
VTP-43742 demonstrated a clear signal of efficacy Biomarker data support, align with clinical results VTP-43742 generally well-tolerated Company believes these data validate RORt as a therapeutic target Company intends to move first-in-class VTP-43742 forward into a 16 week trial to assess full effi
Slide 20: Company Summary
VTP-43742: First-in-class oral RORgt inhibitor, with potential to address significant unmet medical needs within the multi-billion dollar autoimmune markets Initiated clinical trials end of Jun 2015 Announced positive Ph 1a results Sep ‘15; positive Ph 1b Nov ‘15; and positive Ph 2a Mar ‘16 127 volu
Slide 21: Company Summary
Company Summary vita Pharmaceuticals « VTP-43742: First-in-class oral ROR;t inhibitor, with potential to address significant unmet medical needs within the multi-billion dollar autoimmune markets - Initiated clinical trials end of Jun 2015 - Announced positive Ph 1a results Sep ‘15; positive Ph 1b N
Vitae Pharmaceuticals — Corporate Update (March 2016) on 6ix